Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aegerion’s Juxtapid Needs Long-term Post-Market Cohort Study After FDA Nod

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.

You may also be interested in...

Kyle Bass Claims Pink Sheet Article As Prior Art In Juxtapid Patent Challenge

University of Pennsylvania argues neither 2004 article nor slide presentation it describes constitutes prior art that would invalidate method of use claims.

Aegerion’s Lojuxta Submission To Germany's IQWIG Disappoints

IQWIG’s review is now open for consultation, with Germany's top HTA body the G-BA expected to make a final decision about the benefits of the ultra-orphan in December.

One In A Million: Aegerion Looks To Raise The Price Of Myalept

Company sees “opportunity for a one-time price increase” when it takes over the lipodystrophy drug’s launch from AstraZeneca. At a current cost of about $325,000 per year, metreleptin already is on the ultra-high spectrum on par with other rare disease drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts